Bristol Myers cancer therapy meets main goal in late-stage study
BMY•Bristol Myers Squibb said its experimental radiopharmaceutical therapy significantly improved progression-free survival in a late-stage trial of patients with advanced gastrointestinal and pancreatic tumors.
1. Trial results
The trial tested RYZ101 against standard-of-care treatments in patients with gastroenteropancreatic neuroendocrine tumors whose disease had progressed after Lutetium-177-based therapy. Bristol Myers said the drug’s safety profile was consistent with previous studies and that it planned to discuss the data with regulators.
